Potential Alzheimer’s Treatment Targeting Bacteria Seen as Safe in Early Trial, Cortexyme Says
News
COR388, Cortexyme‘s investigational compound to treat Alzheimer’s, was safe and well-tolerated in healthy volunteers taking part in a Phase 1 clinical trial, the company announced. COR388 is a first-in-class bacterial ... Read more